Quantcast
Last updated on April 17, 2014 at 15:37 EDT

Latest Janssen Pharmaceutical Companies Stories

2014-01-08 20:21:24

Ask Agency to require that biosimilars bear distinguishable names to enhance patient safety WASHINGTON, Jan. 8, 2014 /PRNewswire-USNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) today submitted a Citizen Petition to the U.S. Food and Drug Administration (FDA) asking the agency to require biosimilars to bear nonproprietary names that are similar to, but not the same as, those of their reference products or of other biosimilars. The Petition states...

2012-11-29 08:30:07

RARITAN, N.J., Nov. 29, 2012 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced their intention not to enforce the patents they own and control on the antiretroviral (ARV) drug darunavir provided the darunavir product is medically acceptable and is used only in resource-limited settings.(1) This announcement is intended to assure generic manufacturers that they may manufacture high quality darunavir product used in SSA and the LDCs without a concern...

2012-11-10 08:21:37

BOSTON, Massachusetts, November 10, 2012 /PRNewswire/ -- - Study presented at American Association for the Study of Liver Diseases 2012 shows high sustained virological response (SVR) in HCV/HIV co-infected patients receiving INCIVO(R) (telaprevir)-based regimen - Janssen Infectious Diseases-Diagnostics BVBA (Janssen) today presented results from a new phase 2 study which shows that an INCIVO(R) (telaprevir)-based regimen was effective in...

2012-10-29 03:20:51

BEERSE, Belgium, October 29, 2012 /PRNewswire/ -- Pledge Your Support Today to Help Drive Much-needed Change for People With Psoriasis Promising interim results from the Psoriasis Mandate have been released today to mark World Psoriasis Day [http://www.worldpsoriasisday.com ]. To date 1145 people across 40 European countries have pledged their support for five basic rights of people with psoriasis, but experts are urging...

2012-10-16 07:26:13

BEERSE, Belgium, October 16, 2012 /PRNewswire/ -- NOT INTENDED FOR US JOURNALISTS - OPTIMIZE study results to be presented in late-breaking poster presentation at the American Association for the Study of Liver Diseases (AASLD) 2012 show non-inferior sustained virological response (SVR12) rates in previously untreated genotype-1 patients receiving an INCIVO(R) (telaprevir) based regimen twice-daily versus...

2012-10-05 02:23:36

SPRING HOUSE, Pa., Oct. 5, 2012 /PRNewswire/ -- Janssen Research & Development, LLC ("Janssen") announced today that STELARA(®) (ustekinumab) has been awarded the prestigious 2012 International Prix Galien Award at a ceremony in Lyon, France. The Prix Galien Award recognizes extraordinary efforts in biopharmaceutical and medical technology research and development by honoring biomedical advances impacting both individuals and public health in the past decade. The honor is...

2012-07-16 10:25:29

HORSHAM, Pa. and LEIDEN, Netherlands, July 16, 2012 /PRNewswire/ -- Janssen Biotech, Inc. and Janssen Biologics B.V. announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) and a Type II Variation to the European Medicines Agency (EMA) requesting approval of SIMPONI® (golimumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to...

2011-12-08 15:21:00

HORSHAM, Pa., Dec. 8, 2011 /PRNewswire-FirstCall/ -- Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ), announced today that it has executed an agreement with Pharmacyclics, Inc. (Nasdaq: PCYC) to jointly develop and market the anti-cancer compound, PCI-32765. A number of Phase 1 and 2 studies with PCI-32765 are ongoing across a panel of B-cell malignancy disorders, including chronic lymphocytic leukemia, mantle cell lymphoma,...

2011-11-10 13:00:00

TITUSVILLE, N.J., Nov. 10, 2011 /PRNewswire/ -- Janssen Pharmaceutical Companies of Johnson & Johnson ("Janssen") today announced the launch of Healthy Minds, a comprehensive initiative to accelerate progress in the fight against brain disorders that affect millions of people around the world. Healthy Minds includes a significant new commitment by Janssen Pharmaceuticals, Inc. of $3 million in direct and challenge contributions to the International Mental Health Research Organization...

2011-09-23 06:25:00

TITUSVILLE, New Jersey, September 23, 2011 /PRNewswire/ -- - Third HIV medication submitted by Tibotec - Tibotec Pharmaceuticals (Tibotec), one of the Janssen Pharmaceutical Companies, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the approval of EDURANT(R) (rilpivirine), a 25 mg tablet, as a once-daily treatment in combination with other antiretroviral agents...